Research ExplorerPublicationsMelanoma never says die

Melanoma never says die

Standard

Melanoma never says die. / Haass, Nikolas K; Schumacher, Udo.

In: EXP DERMATOL, Vol. 23, No. 7, 07.2014, p. 471-472.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Haass, NK & Schumacher, U 2014, 'Melanoma never says die', EXP DERMATOL, vol. 23, no. 7, pp. 471-472. https://doi.org/10.1111/exd.12400

APA

Haass, N. K., & Schumacher, U. (2014). Melanoma never says die. EXP DERMATOL, 23(7), 471-472. https://doi.org/10.1111/exd.12400

Vancouver

Haass NK, Schumacher U. Melanoma never says die. EXP DERMATOL. 2014 Jul;23(7):471-472. https://doi.org/10.1111/exd.12400

Bibtex

@article{11d5cb13b6cd4698a9e6236698494052,
title = "Melanoma never says die",
abstract = "Drug resistance in melanoma is commonly attributed to ineffective apoptotic pathways. Targeting apoptosis regulators is thus considered a promising approach to sensitizing melanoma to therapy. In this issue of Experimental Dermatology, Pl{\"o}tz & Eberle discuss the role that apoptosis plays in melanoma progression and drug resistance and the utility of apoptosis-inducing BH3-mimetics as targeted therapy. There are a number of compounds in clinical development and the field seems close to translating recent findings into benefits for melanoma patients. Thus this viewpoint is timely and achieves a valuable summary of the current state of apoptosis inducing therapy of melanoma. This article is protected by copyright. All rights reserved.",
author = "Haass, {Nikolas K} and Udo Schumacher",
note = "This article is protected by copyright. All rights reserved.",
year = "2014",
month = jul,
doi = "10.1111/exd.12400",
language = "English",
volume = "23",
pages = "471--472",
journal = "EXP DERMATOL",
issn = "0906-6705",
publisher = "Wiley-Blackwell",
number = "7",

}

RIS

TY - JOUR

T1 - Melanoma never says die

AU - Haass, Nikolas K

AU - Schumacher, Udo

N1 - This article is protected by copyright. All rights reserved.

PY - 2014/7

Y1 - 2014/7

N2 - Drug resistance in melanoma is commonly attributed to ineffective apoptotic pathways. Targeting apoptosis regulators is thus considered a promising approach to sensitizing melanoma to therapy. In this issue of Experimental Dermatology, Plötz & Eberle discuss the role that apoptosis plays in melanoma progression and drug resistance and the utility of apoptosis-inducing BH3-mimetics as targeted therapy. There are a number of compounds in clinical development and the field seems close to translating recent findings into benefits for melanoma patients. Thus this viewpoint is timely and achieves a valuable summary of the current state of apoptosis inducing therapy of melanoma. This article is protected by copyright. All rights reserved.

AB - Drug resistance in melanoma is commonly attributed to ineffective apoptotic pathways. Targeting apoptosis regulators is thus considered a promising approach to sensitizing melanoma to therapy. In this issue of Experimental Dermatology, Plötz & Eberle discuss the role that apoptosis plays in melanoma progression and drug resistance and the utility of apoptosis-inducing BH3-mimetics as targeted therapy. There are a number of compounds in clinical development and the field seems close to translating recent findings into benefits for melanoma patients. Thus this viewpoint is timely and achieves a valuable summary of the current state of apoptosis inducing therapy of melanoma. This article is protected by copyright. All rights reserved.

U2 - 10.1111/exd.12400

DO - 10.1111/exd.12400

M3 - SCORING: Journal article

C2 - 24684560

VL - 23

SP - 471

EP - 472

JO - EXP DERMATOL

JF - EXP DERMATOL

SN - 0906-6705

IS - 7

ER -